Paweł Surowiak

4.7k total citations · 1 hit paper
97 papers, 3.7k citations indexed

About

Paweł Surowiak is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Paweł Surowiak has authored 97 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 37 papers in Molecular Biology and 18 papers in Genetics. Recurrent topics in Paweł Surowiak's work include Drug Transport and Resistance Mechanisms (14 papers), Estrogen and related hormone effects (14 papers) and Ovarian cancer diagnosis and treatment (11 papers). Paweł Surowiak is often cited by papers focused on Drug Transport and Resistance Mechanisms (14 papers), Estrogen and related hormone effects (14 papers) and Ovarian cancer diagnosis and treatment (11 papers). Paweł Surowiak collaborates with scholars based in Poland, Germany and Hungary. Paweł Surowiak's co-authors include Balázs Győrffy, Jan Budczies, András Lánczky, Hermann Lage, M. Zabel, Manfred Dietel, Verena Materna, Adam Maciejczyk, Marek Spaczyński and Rafał Matkowski and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Paweł Surowiak

97 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

2013 1.4k citations Balázs Győrffy, Paweł Surowiak et al. profile →

Peers

Countries citing papers authored by Paweł Surowiak

Since Specialization

Citations

This map shows the geographic impact of Paweł Surowiak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paweł Surowiak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paweł Surowiak more than expected).

Fields of papers citing papers by Paweł Surowiak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paweł Surowiak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paweł Surowiak. The network helps show where Paweł Surowiak may publish in the future.

Co-authorship network of co-authors of Paweł Surowiak

This figure shows the co-authorship network connecting the top 25 collaborators of Paweł Surowiak. A scholar is included among the top collaborators of Paweł Surowiak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paweł Surowiak. Paweł Surowiak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up 2014 ·Oncology Reports ·Piotr Donizy, (unknown), Agnieszka Hałoń, (unknown), Tserenchunt Gansukh, Hermann Lage, Paweł Surowiak, Rafał Matkowski	23
2	The photodynamic effect of far-red range phthalocyanines (AlPc and Pc green) supported by electropermeabilization in human gastric adenocarcinoma cells of sensitive and resistant type 2014 ·Biomedicine & Pharmacotherapy ·(unknown), Jolanta Saczko, Arnold Garbiec, Magda Dubińska–Magiera, Joanna Rossowska, Paweł Surowiak, Anna Choromańska, Małgorzata Daczewska, Julita Kulbacka, Hermann Lage	16
3	Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel 2013 ·Ginekologia Polska ·Adam Maciejczyk, Paweł Surowiak	34
4	[Analysis of BCRP expression in breast cancer patients]. 2012 ·PubMed ·Adam Maciejczyk, Jolanta Szelachowska, (unknown), Rafał Matkowski, Agnieszka Hałoń, Paweł Surowiak	4
5	ABCC2 (MRP2, cMOAT) Localized in the Nuclear Envelope of Breast Carcinoma Cells Correlates with Poor Clinical Outcome 2011 ·Pathology & Oncology Research ·Adam Maciejczyk, (unknown), Teresa Wysocka, Rafał Matkowski, Balázs Győrffy, Hermann Lage, Paweł Surowiak	37
6	PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer 2009 ·British Journal of Cancer ·Gyöngyi Munkácsy, Rula Abdul‐Ghani, Zsuzsanna Mihály, (unknown), Oleg Tchernitsa, Paweł Surowiak, Reinhold Schäfer, Balázs Győrffy	42
7	Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells 2009 ·Bioorganic & Medicinal Chemistry Letters ·Małgorzata Drąg‐Zalesińska, Julita Kulbacka, Jolanta Saczko, Teresa Wysocka, M. Zabel, Paweł Surowiak, Marcin Drąg	82
8	Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. 2008 ·PubMed ·(unknown), Paweł Surowiak, Ewa Nowak‐Markwitz, Marcin Michalak, (unknown), Wojciech Rokitaⴕ, (unknown), M. Zabel, Marek Spaczyński	5
9	Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients 2007 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Verena Materna, Paweł Surowiak, (unknown), (unknown), Zhenfeng Duan, M. Zabel, Manfred Dietel, Hermann Lage	20
10	Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers. 2006 ·SHILAP Revista de lepidopterología ·Paweł Surowiak, (unknown), Balázs Győrffy, Tserenchunt Gansukh, Andrzej Wojnar, Adam Maciejczyk, Marek Pudełko, M. Zabel	35
11	Maspin Expression Is Characteristic for Cisplatin-Sensitive Ovarian Cancer Cells and for Ovarian Cancer Cases of Longer Survival Rates 2006 ·International Journal of Gynecological Pathology ·Paweł Surowiak, Verena Materna, Małgorzata Drąg‐Zalesińska, Andrzej Wojnar, (unknown), (unknown), Manfred Dietel, M. Zabel, Hermann Lage	19
12	ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome 2006 ·Clinical Cancer Research ·Paweł Surowiak, Verena Materna, (unknown), Marek Spaczyński, (unknown), Elżbieta Gębarowska, Manfred Dietel, M. Zabel, Hermann Lage	87
13	Expression of aminopeptidase N/CD13 in human ovarian cancers 2006 ·International Journal of Gynecological Cancer ·Paweł Surowiak, Marcin Drąg, Verena Materna, (unknown), Renata Grzywa, Marek Spaczyński, Manfred Dietel, Józef Oleksyszyn, M. Zabel, Hermann Lage	41
14	Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers 2006 ·British Journal of Cancer ·Paweł Surowiak, Verena Materna, Balázs Győrffy, Rafał Matkowski, Andrzej Wojnar, Adam Maciejczyk, (unknown), Piotr Dzięgiel, Marek Pudełko, Jan Kornafel, Manfred Dietel, Glen Kristiansen, M. Zabel, Hermann Lage	44
15	Complete Reversal of ABCG2-Depending Atypical Multidrug Resistance by RNA Interference in Human Carcinoma Cells 2006 ·Oligonucleotides ·(unknown), Franziska Rompe, Holger Tönnies, (unknown), Paweł Surowiak, A. Stege, Verena Materna, Hermann Lage	23
16	Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade. 2005 ·PubMed ·(unknown), Paweł Surowiak, (unknown), Piotr Dzięgiel, Adam Maciejczyk, Marek Pudełko, Andrzej Wojnar, M. Zabel	1
17	Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance 2005 ·Breast Cancer Research ·Paweł Surowiak, Verena Materna, Rafał Matkowski, (unknown), Jan Kornafel, Andrzej Wojnar, Marek Pudełko, Manfred Dietel, Carsten Denkert, M. Zabel, Hermann Lage	69
18	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations 2005 ·International Journal of Cancer ·Balázs Győrffy, Paweł Surowiak, (unknown), Carsten Denkert, Reinhold Schäfer, Manfred Dietel, Hermann Lage	128
19	Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients 2003 ·European Journal of Internal Medicine ·Tomasz Wróbel, Grzegorz Mazur, Paweł Surowiak, Piotr Dzięgiel, Lidia Usnarska‐Zubkiewicz, Kazimierz Kuliczkowski	10
20	Expression of metallothionein [MT] in synovial sarcoma cells 2001 ·Cellular & Molecular Biology Letters ·Piotr Dzięgiel, Paweł Surowiak, M. Zabel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact